Genitourinary syndrome of menopause in breast cancer survivors: Are we facing new and safe hopes?

Nicoletta Biglia, Valentina E. Bounous, Luca G. Sgro, Marta D'Alonzo, Silvia Pecchio, Rossella E. Nappi

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Breast cancer survivors (BCSs) often suffer from menopausal symptoms induced by systemic treatments, with a consequent negative effect on quality of life. Since the introduction of aromatase inhibitors as the standard therapy for hormone-dependent tumors, genitourinary syndrome of menopause (GSM) has become a main problem for BCSs. This new terminology refers to the wide range of vaginal and urinary symptoms related to menopause, which can be relieved by estrogen therapy. Unfortunately, systemic hormone therapy is contraindicated for BCSs and also vaginal estrogens at standard dosage might influence the risk of recurrence because they cause a significant increase of circulating estrogens. Nonhormonal vaginal moisturizers or lubricants are the first choice for BCSs but only have limited and short-term efficacy. New strategies of management of GSM are now available, including: (1) low-dose or ultra low-dose vaginal estrogens; (2) oral selective estrogen receptor modulators (ospemifene); (3) androgen therapy; (4) physical treatment with vaginal laser; and (5) psychosocial interventions. In this review we discuss and analyze these different options.

Original languageEnglish
Pages (from-to)413-420
Number of pages8
JournalClinical Breast Cancer
Volume15
Issue number6
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Hope
Menopause
Survivors
Breast Neoplasms
Estrogens
Therapeutics
Hormones
Selective Estrogen Receptor Modulators
Lubricants
Aromatase Inhibitors
Terminology
Androgens
Lasers
Quality of Life
Recurrence

Keywords

  • BCS
  • GSM
  • Iatrogenic menopause
  • Treatment
  • Vulvovaginal atrophy (VVA)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Genitourinary syndrome of menopause in breast cancer survivors : Are we facing new and safe hopes? / Biglia, Nicoletta; Bounous, Valentina E.; Sgro, Luca G.; D'Alonzo, Marta; Pecchio, Silvia; Nappi, Rossella E.

In: Clinical Breast Cancer, Vol. 15, No. 6, 01.12.2015, p. 413-420.

Research output: Contribution to journalArticle

Biglia, Nicoletta ; Bounous, Valentina E. ; Sgro, Luca G. ; D'Alonzo, Marta ; Pecchio, Silvia ; Nappi, Rossella E. / Genitourinary syndrome of menopause in breast cancer survivors : Are we facing new and safe hopes?. In: Clinical Breast Cancer. 2015 ; Vol. 15, No. 6. pp. 413-420.
@article{92df62f811374b6fbef6ae1f236567e2,
title = "Genitourinary syndrome of menopause in breast cancer survivors: Are we facing new and safe hopes?",
abstract = "Breast cancer survivors (BCSs) often suffer from menopausal symptoms induced by systemic treatments, with a consequent negative effect on quality of life. Since the introduction of aromatase inhibitors as the standard therapy for hormone-dependent tumors, genitourinary syndrome of menopause (GSM) has become a main problem for BCSs. This new terminology refers to the wide range of vaginal and urinary symptoms related to menopause, which can be relieved by estrogen therapy. Unfortunately, systemic hormone therapy is contraindicated for BCSs and also vaginal estrogens at standard dosage might influence the risk of recurrence because they cause a significant increase of circulating estrogens. Nonhormonal vaginal moisturizers or lubricants are the first choice for BCSs but only have limited and short-term efficacy. New strategies of management of GSM are now available, including: (1) low-dose or ultra low-dose vaginal estrogens; (2) oral selective estrogen receptor modulators (ospemifene); (3) androgen therapy; (4) physical treatment with vaginal laser; and (5) psychosocial interventions. In this review we discuss and analyze these different options.",
keywords = "BCS, GSM, Iatrogenic menopause, Treatment, Vulvovaginal atrophy (VVA)",
author = "Nicoletta Biglia and Bounous, {Valentina E.} and Sgro, {Luca G.} and Marta D'Alonzo and Silvia Pecchio and Nappi, {Rossella E.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.clbc.2015.06.005",
language = "English",
volume = "15",
pages = "413--420",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Genitourinary syndrome of menopause in breast cancer survivors

T2 - Are we facing new and safe hopes?

AU - Biglia, Nicoletta

AU - Bounous, Valentina E.

AU - Sgro, Luca G.

AU - D'Alonzo, Marta

AU - Pecchio, Silvia

AU - Nappi, Rossella E.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Breast cancer survivors (BCSs) often suffer from menopausal symptoms induced by systemic treatments, with a consequent negative effect on quality of life. Since the introduction of aromatase inhibitors as the standard therapy for hormone-dependent tumors, genitourinary syndrome of menopause (GSM) has become a main problem for BCSs. This new terminology refers to the wide range of vaginal and urinary symptoms related to menopause, which can be relieved by estrogen therapy. Unfortunately, systemic hormone therapy is contraindicated for BCSs and also vaginal estrogens at standard dosage might influence the risk of recurrence because they cause a significant increase of circulating estrogens. Nonhormonal vaginal moisturizers or lubricants are the first choice for BCSs but only have limited and short-term efficacy. New strategies of management of GSM are now available, including: (1) low-dose or ultra low-dose vaginal estrogens; (2) oral selective estrogen receptor modulators (ospemifene); (3) androgen therapy; (4) physical treatment with vaginal laser; and (5) psychosocial interventions. In this review we discuss and analyze these different options.

AB - Breast cancer survivors (BCSs) often suffer from menopausal symptoms induced by systemic treatments, with a consequent negative effect on quality of life. Since the introduction of aromatase inhibitors as the standard therapy for hormone-dependent tumors, genitourinary syndrome of menopause (GSM) has become a main problem for BCSs. This new terminology refers to the wide range of vaginal and urinary symptoms related to menopause, which can be relieved by estrogen therapy. Unfortunately, systemic hormone therapy is contraindicated for BCSs and also vaginal estrogens at standard dosage might influence the risk of recurrence because they cause a significant increase of circulating estrogens. Nonhormonal vaginal moisturizers or lubricants are the first choice for BCSs but only have limited and short-term efficacy. New strategies of management of GSM are now available, including: (1) low-dose or ultra low-dose vaginal estrogens; (2) oral selective estrogen receptor modulators (ospemifene); (3) androgen therapy; (4) physical treatment with vaginal laser; and (5) psychosocial interventions. In this review we discuss and analyze these different options.

KW - BCS

KW - GSM

KW - Iatrogenic menopause

KW - Treatment

KW - Vulvovaginal atrophy (VVA)

UR - http://www.scopus.com/inward/record.url?scp=84947040451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947040451&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2015.06.005

DO - 10.1016/j.clbc.2015.06.005

M3 - Article

C2 - 26198332

AN - SCOPUS:84947040451

VL - 15

SP - 413

EP - 420

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 6

ER -